What’s the current market cap for Doximity stock?

Doximity (DOCS) has a market cap of $4.2bn as of July 08, 2026.

What is the P/E ratio for Doximity stock?

The price to earnings (P/E) ratio for Doximity (DOCS) stock is 23.2 as of July 08, 2026.

Does Doximity stock pay dividends?

No, Doximity (DOCS) stock does not pay dividends to its shareholders as of July 08, 2026.

When is the next Doximity dividend payment date?

Doximity (DOCS) stock does not pay dividends to its shareholders.

What is the beta indicator for Doximity?

Doximity (DOCS) has a beta rating of 1.35. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy Doximity stock | $DOCS Share Price

13:30

15:10

16:45

18:25

20:00

About Doximity

Doximity Inc provides an online platform, which enables physicians and other healthcare professionals to collaborate with colleagues, stay up to date with the latest medical news and research, manage their careers and on-call schedules, streamline documentation and administrative paperwork, and conduct virtual patient visits. The Company's customers include pharmaceutical companies and health systems that connect with healthcare professionals through the Company's digital Marketing, Hiring, and Workflow Solutions. Marketing Solutions provide customers with the ability to share tailored content on the network. Hiring Solutions enable customers to identify, connect with, and hire from the network of both active and passive potential medical professional candidates.

Ticker

$DOCS

Sector

Health

Primary listing

NYSE

Employees

880

Headquarters

San Francisco, United States

Website

www.doximity.com

Doximity Metrics

BasicAdvanced

$4.2bn

23.20

$0.98

1.35

What the Analysts think about Doximity

Analyst ratings (Buy, Hold, Sell) for Doximity stock.

Bulls say / Bears say

Q3 FY2026 revenue grew 10% year-over-year to $185.1 million, with adjusted EBITDA margins holding above 60% and record engagement metrics—over 1 million active prescribers in the newsfeed, 720,000 using workflow tools, and 300,000 engaging with new AI products—underscoring strong platform adoption (SEC).

Fiscal 2026 revenue reached $644.9 million, a 13% increase year-over-year, while operating cash flow and free cash flow both rose 19%, highlighting robust cash generation and financial resilience (SEC).

Doximity Dialer was named the #1 Best in KLAS Telehealth Video Platform for the fifth consecutive year, demonstrating sustained product leadership and differentiation in the telehealth market (BusinessWire).

Non-GAAP net income margins in Q4 FY2026 fell from 56.2% to 34.2%, and adjusted EBITDA declined 6% year-over-year, signaling significant margin compression amidst rising operating costs (SEC).

Operating cash flow and free cash flow in Q3 FY2026 decreased by 7% and 8% respectively year-over-year, indicating pressure on cash generation due to elevated R&D and sales investments (SEC).

Guidance for Q1 FY2027 implies only 4% year-over-year revenue growth, and FY2027 outlook projects just 3–5% growth, marking a deceleration from prior year double-digit gains and raising concerns about future expansion (SEC).

Data summarised monthly by Lightyear AI. Last updated on 27 Jun 2026.

Doximity Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

Doximity Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Bulls say / Bears say

Non-GAAP net income margins in Q4 FY2026 fell from 56.2% to 34.2%, and adjusted EBITDA declined 6% year-over-year, signaling significant margin compression amidst rising operating costs (SEC).

Operating cash flow and free cash flow in Q3 FY2026 decreased by 7% and 8% respectively year-over-year, indicating pressure on cash generation due to elevated R&D and sales investments (SEC).

Data summarised monthly by Lightyear AI. Last updated on 27 Jun 2026.